Alliance Global Partners lowered the firm’s price target on Journey Medical (DERM) to $10.50 from $11 and keeps a Buy rating on the shares. Journey Medical’s Q4 earnings results were at the lower end of the firm’s expectations, the analyst tells investors in a research note. The firm is targeting 2025 as an inflection year given the launch of the rosacea treatment Emrosi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Journey Medical Corporation Reports 2024 Financial Results
- Journey Medical reports FY24 EPS (72c) vs (21c) last year
- Journey Medical launches Emrosi for the treatment of rosacea
- Journey Medical Corporation (DERM) Q4 Earnings Cheat Sheet
- Journey Medical announces results from MVOR-1, MVOR-2 trials published